April 12, 2021ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)108 citationsOpen Access
View Full PaperProspective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics
Structured PICO
Does sacubitril/valsartan prevent development of heart failure and cardiovascular death compared to an ACE inhibitor in patients following acute myocardial infarction?
P
Population
Patients following acute myocardial infarction (AMI)
I
Intervention
Sacubitril/valsartan
C
Comparator
Proven ACE inhibitor
O
Outcome
Development of heart failure and cardiovascular deathcomposite
The PARADISE-MI trial is designed to evaluate whether sacubitril/valsartan is superior to an ACE inhibitor in preventing heart failure and cardiovascular death after acute myocardial infarction.
Abstract
Baseline therapies in PARADISE-MI reflect advances in contemporary evidence-based care. With enrollment complete PARADISE-MI is poised to determine whether sacubitril/valsartan is more effective than a proven ACE inhibitor in preventing development of HF and cardiovascular death following AMI.
Cite This Study
Jering et al. (Mon,) studied this question.